Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The last earnings update was 17 days ago. More info.
Add to Portfolio Compare Print
- Akebia Therapeutics has significant price volatility in the past 3 months.
AKBA Share Price and Events
7 Day Returns
1 Year Returns
AKBA Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Akebia Therapeutics (AKBA) | -4.7% | -17.7% | -29.8% | -49.1% | -40.5% | -78.4% |
| US Biotechs | 0.3% | -1.4% | -4.9% | -4.9% | 3.6% | 11% |
| US Market | -1.4% | -3.9% | 0.2% | 1.6% | 33.2% | 38.2% |
1 Year Return vs Industry and Market
- AKBA underperformed the Biotechs industry which returned -4.9% over the past year.
- AKBA underperformed the Market in United States of America which returned 1.6% over the past year.
AKBA Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Akebia Therapeutics
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Akebia Therapeutics.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 9 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 10.5% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.38 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.383 (1 + (1- 21%) (5.83%)) |
1.299 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.3 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.299 * 5.96%) |
10.47% |
Discounted Cash Flow Calculation for NasdaqGM:AKBA using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Akebia Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 10.47%) |
|
|---|---|---|---|
| 2019 | -226.00 | Analyst x1 | -204.58 |
| 2020 | -142.01 | Analyst x2 | -116.36 |
| 2021 | -15.66 | Analyst x2 | -11.61 |
| 2022 | 109.69 | Analyst x1 | 73.65 |
| 2023 | 211.68 | Analyst x1 | 128.65 |
| 2024 | 307.52 | Est @ 45.28% | 169.19 |
| 2025 | 407.50 | Est @ 32.51% | 202.94 |
| 2026 | 503.58 | Est @ 23.58% | 227.02 |
| 2027 | 590.82 | Est @ 17.32% | 241.10 |
| 2028 | 667.30 | Est @ 12.95% | 246.50 |
| Present value of next 10 years cash flows | $956.50 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $667.30 × (1 + 2.73%) ÷ (10.47% – 2.73%) |
$8,855.03 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $8,855.03 ÷ (1 + 10.47%)10 |
$3,271.03 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $956.50 + $3,271.03 |
$4,227.52 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $4,227.52 / 117.86 |
$35.87 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $35.87 |
| Current discount | Discount to share price of
$5.24
= -1 x ($5.24 - $35.87) / $35.87 |
85.4% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Akebia Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Akebia Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Akebia Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Akebia Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-2.56 |
| NasdaqGM:AKBA Share Price ** | NasdaqGM (2019-05-24) in USD | $5.24 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 35 Publicly-Listed Biotechs Companies | 18.23x |
| United States of America Market PE Ratio | Median Figure of 3,084 Publicly-Listed Companies | 17.44x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Akebia Therapeutics.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGM:AKBA Share Price ÷ EPS (both in USD) = 5.24 ÷ -2.56 |
-2.04x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Akebia Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
- Akebia Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Akebia Therapeutics's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -2.04x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts |
71.4%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 28 Publicly-Listed Biotechs Companies | 1.22x |
| United States of America Market PEG Ratio | Median Figure of 2,121 Publicly-Listed Companies | 1.51x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Akebia Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Akebia Therapeutics's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $4.84 |
| NasdaqGM:AKBA Share Price * | NasdaqGM (2019-05-24) in USD | $5.24 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 416 Publicly-Listed Biotechs Companies | 3.17x |
| United States of America Market PB Ratio | Median Figure of 5,207 Publicly-Listed Companies | 1.8x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGM:AKBA Share Price ÷ Book Value per Share (both in USD) = 5.24 ÷ 4.84 |
1.08x |
* Primary Listing of Akebia Therapeutics.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Akebia Therapeutics is good value based on assets compared to the US Biotechs industry average.
Value checks
We assess Akebia Therapeutics's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Akebia Therapeutics has a total score of 3/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
AKBA Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Akebia Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Akebia Therapeutics's earnings growth is expected to exceed the United States of America market average.
- Akebia Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGM:AKBA Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts | 71.4% |
| NasdaqGM:AKBA Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts | 20.2% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 22.6% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 17.7% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.7% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 9 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 732 | 424 | 4 | |
| 2022-12-31 | 567 | 295 | 4 | |
| 2021-12-31 | 418 | -152 | 66 | 6 |
| 2020-12-31 | 366 | -41 | -100 | 9 |
| 2019-12-31 | 351 | -225 | -155 | 8 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 234 | -215 | -193 |
| 2018-12-31 | 208 | -97 | -144 |
| 2018-09-30 | 235 | -40 | -71 |
| 2018-06-30 | 223 | -82 | -68 |
| 2018-03-31 | 206 | -67 | -53 |
| 2017-12-31 | 181 | -56 | -74 |
| 2017-09-30 | 92 | 56 | -127 |
| 2017-06-30 | 51 | 82 | -140 |
| 2017-03-31 | 22 | 31 | -154 |
| 2016-12-31 | 2 | 58 | -136 |
| 2016-09-30 | -61 | -118 | |
| 2016-06-30 | -41 | -101 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 9 Analyst Estimates (S&P Global) | See Below |
All data from Akebia Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 2.88 | 2.95 | 2.81 | 2.00 |
| 2022-12-31 | 2.06 | 2.12 | 2.00 | 2.00 |
| 2021-12-31 | 0.50 | 0.50 | 0.50 | 1.00 |
| 2020-12-31 | -0.62 | -0.22 | -0.90 | 6.00 |
| 2019-12-31 | -1.35 | -0.72 | -1.80 | 7.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -2.56 |
| 2018-12-31 | -2.47 |
| 2018-09-30 | -1.36 |
| 2018-06-30 | -1.37 |
| 2018-03-31 | -1.14 |
| 2017-12-31 | -1.69 |
| 2017-09-30 | -3.08 |
| 2017-06-30 | -3.60 |
| 2017-03-31 | -4.05 |
| 2016-12-31 | -3.60 |
| 2016-09-30 | -3.29 |
| 2016-06-30 | -3.01 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Akebia Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Future performance checks
We assess Akebia Therapeutics's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Akebia Therapeutics has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
AKBA Past Performance
How has Akebia Therapeutics performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Akebia Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Akebia Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Akebia Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Akebia Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 234.48 | -192.59 | 89.23 | |
| 2018-12-31 | 207.74 | -143.59 | 63.96 | |
| 2018-09-30 | 235.21 | -71.25 | 39.51 | |
| 2018-06-30 | 223.32 | -68.34 | 35.88 | |
| 2018-03-31 | 206.29 | -52.55 | 30.24 | |
| 2017-12-31 | 181.23 | -73.67 | 27.01 | |
| 2017-09-30 | 92.20 | -127.06 | 25.59 | |
| 2017-06-30 | 50.92 | -140.23 | 23.78 | |
| 2017-03-31 | 22.40 | -154.49 | 22.19 | |
| 2016-12-31 | 1.54 | -135.75 | 22.21 | |
| 2016-09-30 | -117.74 | 21.87 | -28.77 | |
| 2016-06-30 | -100.91 | 21.00 | -13.17 | |
| 2016-03-31 | -75.82 | 20.08 | -6.56 | |
| 2015-12-31 | -60.72 | 18.50 | ||
| 2015-09-30 | -51.23 | 18.07 | 33.61 | |
| 2015-06-30 | -41.10 | 17.23 | 24.65 | |
| 2015-03-31 | -38.03 | 15.18 | 23.57 | |
| 2014-12-31 | -123.93 | 14.68 | ||
| 2014-09-30 | -122.54 | 12.01 | 21.52 | |
| 2014-06-30 | -119.70 | 9.57 | 18.11 | |
| 2014-03-31 | -164.18 | 7.90 | 15.04 | |
| 2013-12-31 | -69.05 | 7.03 | 8.90 | |
| 2013-09-30 | -63.34 | 3.44 | 8.16 | |
| 2012-12-31 | -11.52 | 2.89 | 5.63 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Akebia Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Akebia Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Akebia Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Akebia Therapeutics's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Akebia Therapeutics has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
AKBA Health
How is Akebia Therapeutics's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Akebia Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
- Akebia Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Akebia Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 9.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Akebia Therapeutics Company Filings, last reported 1 month ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 566.38 | 35.98 | 168.04 |
| 2018-12-31 | 635.93 | 15.00 | 321.64 |
| 2018-09-30 | 142.54 | 0.00 | 390.14 |
| 2018-06-30 | 165.92 | 0.00 | 402.12 |
| 2018-03-31 | 197.10 | 0.00 | 393.03 |
| 2017-12-31 | 122.57 | 0.00 | 317.79 |
| 2017-09-30 | 99.88 | 0.01 | 329.71 |
| 2017-06-30 | 57.00 | 0.01 | 321.22 |
| 2017-03-31 | 30.62 | 0.01 | 251.81 |
| 2016-12-31 | 68.12 | 0.00 | 260.34 |
| 2016-09-30 | 100.71 | 0.01 | 161.32 |
| 2016-06-30 | 133.29 | 0.01 | 188.65 |
| 2016-03-31 | 167.76 | 0.01 | 217.03 |
| 2015-12-31 | 131.00 | 0.00 | 138.45 |
| 2015-09-30 | 145.41 | 0.00 | 157.47 |
| 2015-06-30 | 149.75 | 0.00 | 152.79 |
| 2015-03-31 | 94.61 | 0.00 | 100.33 |
| 2014-12-31 | 104.08 | 0.00 | 108.92 |
| 2014-09-30 | 113.61 | 0.00 | 118.34 |
| 2014-06-30 | 121.55 | 0.01 | 124.25 |
| 2014-03-31 | 127.87 | 0.01 | 132.15 |
| 2013-12-31 | 30.76 | 0.00 | 32.56 |
| 2013-09-30 | 35.57 | 0.00 | 37.72 |
| 2012-12-31 | 1.47 | 0.00 | 1.64 |
- Akebia Therapeutics's level of debt (6.4%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0% vs 6.4% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Akebia Therapeutics has less than a year of cash runway based on current free cash flow.
- Akebia Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 64.8% each year.
Financial health checks
We assess Akebia Therapeutics's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Akebia Therapeutics has a total score of 3/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
AKBA Dividends
What is Akebia Therapeutics's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Akebia Therapeutics
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Akebia Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Akebia Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 9 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2007 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | 0.00 | 1.00 |
| 2020-12-31 | 0.00 | 1.00 |
| 2019-12-31 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Akebia Therapeutics has not reported any payouts.
- Unable to verify if Akebia Therapeutics's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Akebia Therapeutics's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Akebia Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Akebia Therapeutics has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
AKBA Management
CEO
| COMPENSATION | $3,471,072 |
| AGE | 54 |
| TENURE AS CEO | 5.7 years |
CEO Bio
Mr. John P. Butler, MBA, has been the Chief Executive Officer and President of Akebia Therapeutics, Inc. since September 2013. Mr. Butler served as Chief Executive Officer of Inspiration Biopharmaceuticals, Inc. from October 11, 2011 to April 2013. He served as the President of Personalized Genetic Health at Genzyme Corporation since May 2010. He served as Senior Vice President and President of Cardiometabolic & Renal at Genzyme Corporation. He served as President of Renal business of Genzyme Corporation. He served as Senior Vice President and General Manager of the Renal business of Genzyme Corporation since July 16, 2003. Mr. Butler has more than 25 years of experience commercializing innovative therapies, leading businesses that served rare disease patient populations. He joined Genzyme in 1997 as Product Manager for Renagel and served as its Vice President of strategic planning and Vice President of Renagel Europe. He served as President of the Rare Genetic Diseases Business at Genzyme Corporation. From 2002 to 2010, Mr. Butler led Genzyme's renal division. Prior to his work at Genzyme from 1997 to 2011, he worked in sales and marketing at Amgen Inc., and Hoffmann-La Roche. He served as a Director of Relypsa, Inc. from September 26, 2013 to 2016. He has been a Director of Akebia Therapeutics, Inc. since July 2013. He has been a Chairperson of the Board of Keryx Biopharmaceuticals, Inc. since December 12, 2018. He has been a Director of Zynerba Pharmaceuticals, Inc. since April 2018. He was Chairman of Keryx Biopharmaceuticals from 2015 to 2017. He served as an Independent Director of Keryx Biopharmaceuticals Inc. from December 10, 2015 to September 13, 2017. He served as a Director of Inspiration Biopharmaceuticals, Inc. He served as Chairman of the Board of Trustees for the American Kidney Fund from 2013 to 2015. Mr. Butler has an M.B.A. from Baruch College, City University of New York and a B.A. in Chemistry from Manhattan College.
CEO Compensation
- John's compensation has increased whilst company is loss making.
- John's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Akebia Therapeutics management team in years:
- The tenure for the Akebia Therapeutics management team is about average.
Management Team
John Butler
CEO, President & Director
$3M
54
5.7 yrs
Jason Amello
Senior VP
$1M
50
5.7 yrs
Rita Jain
Senior VP & Chief Medical Officer
$1M
56
2 yrs
Kristen Sheppard
Vice President of Investor Relations
Nikki Hadas
SVP, Chief Legal Officer & Secretary
45
6.3 yrs
Doug Jermasek
Vice President of Marketing & Strategy
Tamara Dillon
Senior Vice President of Human Resources
2.5 yrs
Michel Dahan
Senior VP & Chief Business Officer
$1M
39
3.6 yrs
Karen Tubridy
Senior VP & Chief Development Officer
56
2.5 yrs
Dell Faulkingham
Senior VP & Chief Commercial Officer
Board of Directors Tenure
Average tenure and age of the Akebia Therapeutics board of directors in years:
- The average tenure for the Akebia Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors
Adrian Adams
Chairperson
$133K
67
0.4 yrs
John Butler
CEO, President & Director
$3M
54
5.8 yrs
Cynthia Smith
Director
$155K
49
0.8 yrs
Michael Rogers
Director
$133K
58
0.4 yrs
Randall Johnson
Advisor & Member of Scientific Advisory Board
71
John Adamson
Peter Hutt
83
Frank Bunn
Suzette Dutch
Observer
Volker Haase
Advisor & Member of Scientific Advisory Board
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 21. Dec 18 | Sell | Nantahala Capital Management, LLC | Company | 22. Oct 18 | 17. Dec 18 | -99,931 | $8.61 | $-844,804 | ||
| 21. Dec 18 | Buy | Nantahala Capital Management, LLC | Company | 20. Nov 18 | 20. Dec 18 | 410,577 | $8.50 | $2,965,981 | ||
| 26. Sep 18 | Buy | Nantahala Capital Management, LLC | Company | 07. Aug 18 | 10. Sep 18 | 201,100 | $9.99 | $1,761,812 | ||
Management checks
We assess Akebia Therapeutics's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Akebia Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
AKBA News
Simply Wall St News
Do Institutions Own Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares?
Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … We also tend to see lower insider ownership in companies that were previously publicly owned. … It has a market capitalization of US$955m, which means it would generally expect to see some institutions on the share registry.
Simply Wall St - – Full articleSome Akebia Therapeutics Shareholders Have Copped A Big 50% Share Price Drop
(NASDAQ:AKBA) shareholders should be happy to see the share price up 29% in the last month. … Like an arid lake in a warming world, shareholder value has evaporated, with the share price down 50% in that time. … Akebia Therapeutics isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS).
Simply Wall St - – Full articleWhat does Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Balance Sheet Tell Us About Its Future?
(NASDAQ:AKBA), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … While AKBA has no debt on its balance sheet, it doesn’t necessarily mean it exhibits financial strength. … Does AKBA's growth rate justify its decision for financial flexibility over lower cost of capital
Simply Wall St - – Full articleHow Does Akebia Therapeutics, Inc. (NASDAQ:AKBA) Affect Your Portfolio Volatility?
(NASDAQ:AKBA), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility).
Simply Wall St - – Full articleHow Much is Akebia Therapeutics Inc's (NASDAQ:AKBA) CEO Getting Paid?
This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does John Butler's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Akebia Therapeutics Inc has a market cap of US$396m, and is paying total annual CEO compensation of US$3.4m
Simply Wall St - – Full articleHow Financially Strong Is Akebia Therapeutics Inc (NASDAQ:AKBA)?
The direct benefit for Akebia Therapeutics Inc (NASDAQ:AKBA), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is AKBA will have to adhere to stricter debt covenants and have less financial flexibility. … Is financial flexibility worth the lower cost of capital.
Simply Wall St - – Full articleIs Akebia Therapeutics Inc's (NASDAQ:AKBA) CEO Incentives Align With Yours?
John Butler is the CEO of Akebia Therapeutics Inc (NASDAQ:AKBA), which has recently grown to a market capitalization of US$565.72m. … Recognizing whether CEO incentives are aligned with shareholders is a crucial part of investing. … This is because, if incentives are aligned, more value is created for shareholders which directly impacts your returns as an investor.
Simply Wall St - – Full articleWhat You Must Know About Akebia Therapeutics Inc's (NASDAQ:AKBA) Financial Strength
However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is financial flexibility worth the lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.
Simply Wall St - – Full articleWill Akebia Therapeutics Inc's (NASDAQ:AKBA) Earnings Grow Over The Next Few Years?
Akebia Therapeutics Inc's (NASDAQ:AKBA) most recent earnings update in December 2017 indicated that losses became smaller relative to the prrior year's level as a result of recent tailwinds Investors may find it useful to understand how market analysts view Akebia Therapeutics's earnings growth outlook over the next few years and whether the future looks brighter. … NasdaqGM:AKBA Future Profit May 7th 18 While it’s informative understanding the growth rate year by year relative to today’s value, it may be more valuable gauging the rate at which the company is growing on average every year. … This means that, we can presume Akebia Therapeutics will grow its earnings by 33.20% every year for the next couple of years.
Simply Wall St - – Full articleWhen Will Akebia Therapeutics Inc (NASDAQ:AKBA) Become Profitable?
Akebia Therapeutics Inc's (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. … View our latest analysis for Akebia Therapeutics Expectation from analysts is AKBA is on the verge of breakeven. … This means that a high growth rate is not unusual, especially if the company is currently in an investment period.
Simply Wall St - – Full articleAKBA Company Info
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Details
| Name: | Akebia Therapeutics, Inc. |
| AKBA | |
| Exchange: | NasdaqGM |
| Founded: | 2007 |
| $617,599,982 | |
| 117,862,592 | |
| Website: | http://www.akebia.com |
| Address: |
Akebia Therapeutics, Inc. 245 First Street, Suite 1400, Cambridge, Massachusetts, 02142, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGM | AKBA | Common Stock | Nasdaq Global Market | US | USD | 20. Mar 2014 | |
| DB | AX9 | Common Stock | Deutsche Boerse AG | DE | EUR | 20. Mar 2014 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/26 00:40 |
| End of day share price update: | 2019/05/24 00:00 |
| Last estimates confirmation: | 2019/05/15 |
| Last earnings filing: | 2019/05/09 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
